Revenue Projections - The company expects 2025 annual revenue to be between RMB 1,950 million and RMB 2,150 million, an increase of RMB 569.62 million to RMB 769.62 million, representing a year-on-year growth of 41.27% to 55.75%[4]. - The previous year's revenue was RMB 1,380.38 million, with a net profit attributable to the parent company of RMB -115.25 million[5]. Profit Projections - The projected net profit attributable to the parent company for 2025 is expected to be between RMB 48 million and RMB 72 million, an increase of RMB 59.52 million to RMB 83.52 million, achieving a turnaround from loss to profit[4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between RMB -145 million and RMB -100 million, a decrease of RMB 20.89 million to an increase of RMB 24.10 million compared to the previous year[4]. Factors Influencing Growth - The company attributes the revenue growth to breakthroughs in core technology, continuous industrialization, and product upgrades, enhancing competitive advantages in technology, customer resources, and product coverage[7]. - The company anticipates that the scale effect will gradually become apparent, with R&D investment steadily increasing but its proportion of revenue decreasing year-on-year, leading to improved profitability[7]. Earnings Forecast Validity - The earnings forecast is based on preliminary calculations by the company's finance department and has not yet been audited by registered accountants[8]. - There are no significant uncertainties affecting the accuracy of this earnings forecast[8]. - Investors are advised that the above forecast data is preliminary and the specific financial data will be disclosed in the official 2025 annual report[9].

Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2025 to be between 49.6 million and 74.4 million CNY, representing a decrease of 22.94 million to 25.42 million CNY, or a decline of 75.51% to 83.68% compared to the previous year [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 1.3 million and 1.95 million CNY, a decrease of 23.27 million to 23.33 million CNY, or a decline of 99.17% to 99.45% year-on-year [5]. - The total profit for the previous year was 368.13 million CNY, with a net profit attributable to shareholders of 303.83 million CNY and a net profit after deducting non-recurring gains and losses of 234.62 million CNY [6]. Factors Influencing Profit Decline - The decline in net profit is primarily due to the impact of macroeconomic and market changes on the chemical sector, leading to a decrease in prices of key products such as soda ash [7]. - The company anticipates non-operating gains and losses to be approximately 64 million CNY, influenced by factors such as government subsidies and asset disposal gains [8]. Strategic Focus and Management - The company will continue to focus on its core business and innovation-driven development, implementing lean management and cost reduction measures to enhance market competitiveness [7]. - The earnings forecast is based on preliminary estimates and has not been audited by an accounting firm, with no significant uncertainties expected to affect the accuracy of the forecast [10]. - The data provided is preliminary and the final financial figures will be disclosed in the official 2025 annual report [11].

证券代码：688331 证券简称：荣昌生物 公告编号：2026-006 港股代码：09995 港股简称：榮昌生物 （2）公司预计 2025 年度实现归属于母公司所有者的净利润约 71,600 万元， 与上年同期相比，实现扭亏为盈。 （3）公司预计 2025 年度归属于母公司所有者扣除非经常性损益后的净利润 约 7,850 万元，与上年同期相比，实现扭亏为盈。 （三）本期业绩预告相关的财务数据未经注册会计师预审计。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经荣昌生物制药（烟台）股份有限公司（以下简称"公司"）财务部 门初步测算，预计 2025 年度营业收入约 325,000 万元，与上年同期相比，将增 加收入约 153,314 万元，同比增加约 89%。 荣昌生物制药（烟台）股份有限公司 2025 年年度业绩预告 二、上年同期业绩情况 2024 年度营业收入 171,686.17 万 ...

Financial Performance - The company expects a net profit of approximately -19,000 million CNY for the year 2025, compared to -14,500 million CNY in the same period last year[4] - The net profit after deducting non-recurring gains and losses is projected to be -19,500 million CNY, down from -15,000 million CNY year-over-year[4] - The decline in performance is attributed to delays in major project execution, increased R&D investments, and business restructuring of subsidiaries, leading to a planned goodwill impairment of approximately 11,200 million CNY[6] Business Strategy - The company has nearly 1 billion CNY in hand orders at the end of the reporting period, showing significant growth compared to the same period last year[7] - The management emphasizes a focus on core businesses such as rail transit, national defense, and civil aviation, aiming to optimize resource allocation and integrate AI and 5G technologies into main operations[7] - The company plans to enhance customer collaboration and ensure the execution and delivery of existing orders while advancing lean management and digital transformation[7] Investor Guidance - The financial data will be detailed in the company's 2025 annual report, and investors are advised to make cautious decisions[8]

Revenue Projections - The company expects to achieve approximately CNY 4.391 billion in revenue for the year 2025, representing a year-on-year increase from CNY 4.349 billion in 2024[4][6]. - The company anticipates a total sales collection of approximately CNY 5.14 billion for 2025, reflecting a year-on-year growth of about 8.03%[8]. Profit and Loss Forecast - The net profit attributable to the parent company is projected to be between CNY -1.358 billion and CNY -1.134 billion, indicating a reduction in losses by CNY 20.56 million to CNY 244.95 million, a year-on-year improvement of 1.49% to 17.76%[4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between CNY -1.595 billion and CNY -1.332 billion, with a reduction in losses of CNY 16.51 million to CNY 279.96 million, a year-on-year improvement of 1.02% to 17.37%[4]. Cash Flow and Expenses - The net cash flow from operating activities is expected to be around CNY -61 million, showing an improvement of approximately CNY 281 million, marking the best cash flow level since the company went public[8]. - The company has reduced its three major expenses (selling, research and management) by approximately 16% year-on-year[8]. Business Strategy and Operations - The company has focused on large customers and core products, successfully securing multiple large orders worth tens of millions[8]. - New products such as AISOC and the Large Model Guardian have been successfully scaled in application among customers[8]. Financial Reporting and Audit - The performance forecast has not been audited by a registered accountant and is based on preliminary calculations by the company's financial department[10]. - The company has made provisions for asset impairment based on cautious principles, which will impact the current profit[9].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 证券代码：301008 证券简称：宏昌科技 公告编号：2026-006 浙江宏昌电器科技股份有限公司 2025 年度业绩预告 二、与会计师事务所沟通情况 本次业绩预告的相关数据未经会计师事务所审计。公司已就本次业绩预告有 关事项与会计师事务所进行预沟通，公司与会计师事务所在业绩预告方面不存在 分歧。 三、业绩变动原因说明 报告期内因计提公司可转债利息、员工持股计划的股份支付及原材料价格上 涨等原因共同增加所致。 四、其他相关说明 本次业绩预告为公司财务部门初步测算的结果，未经会计师事务所审计，具 体财务数据公司将在2025年度报告中详细披露。敬请广大投资者审慎决策， 注 意投资风险。 一、本期业绩预计情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 □扭亏为盈 □同向上升 同向下降 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股 | 盈利：2,098.63万元至2,623.29万元 | 盈利：5,246.57 ...

华熙生物科技股份有限公司 2025 年年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 证券代码：688363 证券简称：华熙生物 公告编号：2026-003 二、上年同期业绩情况和财务状况 （一）利润总额：21,339.29 万元。归属于母公司所有者的净利润：17,426.74 万元。归属于母公司所有者的扣除非经常性损益的净利润：10,727.20 万元。 （二）每股收益：0.36 元。 三、本期业绩变化的主要原因 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经华熙生物科技股份有限公司（以下简称"公司"）财务部门初步测 算，预计 2025 年年度实现归属于母公司所有者的净利润人民币 27,000.00 万元到 32,000.00 万元，与上年同期（法定披露数据）相比，将增加 9,573.26 万元到 14,573.26 万元，同比增加 54.93%到 83.63%。 （2）预计 2025 年年度实现归属于母公司所有 ...

证券代码：603685 证券简称：晨丰科技 公告编号：2026-003 浙江晨丰科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比上升 50% 以上。 浙江晨丰科技股份有限公司（以下简称"公司"）预计 2025 年年度实现 归属于母公司所有者的净利润 1,755.08 万元到 2,632.62 万元；实现归属于母公 司所有者的扣除非经常性损益的净利润-1,260.36 万元到-840.24 万元。 2025 年 5 月，公司完成收购辽宁北网新能电力科技股份有限公司（以下简 称"北网新能"，原名"辽宁盛帆新能源工程股份有限公司"）94.2752%股权， 北网新能成为公司的控股孙公司，纳入公司合并报表范围。根据企业会计准则相 关规定，公司按照同一控制下企业合并的相关规定对上年同期数据进行追溯调 整： （一）追溯调整前 1.利润总额：-71.77 万元。归属于母公司所有者的净利润：1,108.70 万元。 归属于母公司所 ...

Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between 8.6 million and 12.9 million yuan, representing a decline of 76.65% to 84.43% compared to the previous year's profit of 55.25 million yuan [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 8.14 million and 12.21 million yuan, reflecting a decrease of 76.85% to 84.57% from last year's figure of 52.74 million yuan [3]. Impairment and Expenses - The company plans to recognize impairment provisions for accounts receivable, inventory, and intangible assets, negatively impacting the current period's performance [5]. - The increase in the period expense ratio compared to the same period last year is attributed to intensified R&D investments for smart product business transformation and increased depreciation from fixed assets [5]. Revenue and Margin - The company's operating revenue remains flat compared to the previous year, with a slight decline in overall gross margin due to a decrease in the proportion of higher-margin export business [5].

（1）以区间数进行业绩预告的 证券代码：301136 证券简称：招标股份 公告编号：2026-009 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 单位：万元 | 项 目 | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公 司股东的净利 | -1,260 | ～ | -630 | -611.05 | | 润 | | | | | | 扣除非经常性 | | | | | | 损益后的净利 | -1,900 | ～ | -950 | -1,416.9 | | 润 | | | | | 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与 会计师事务所在本报告期的业绩预告方面不存在重大分歧。 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所 审计。 2、本报告期内，公司应收账款（合同资产）回款周期有所延长。为遵循谨慎 性原则，公司计提了坏账准备及商誉减值损失，影响本期经营业绩。 本报告期业绩预计亏损的主要原因如下： 1、本报告期内，公司业务承接量 ...